SECAUCUS, N.J., May 6, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, announced today that Murali Balakumar, a veteran information technology healthcare business leader, has been named Senior Vice President and Chief Information and Digital Officer (CIDO).Mr. Balakumar, based at the company's headquarters in Secaucus, N.J., is responsible for leading information technology, data informatics and digital solutions for Quest Diagnostics. Murali Bal ...

Quest Diagnostics (DGX) recently announced a multi-faceted collaboration with PathAI to accelerate the adoption of digital and AI pathology innovations to improve quality, speed and efficiency in diagnosing cancer and other diseases. Under a definitive agreement, the company will acquire select assets of PathAI Diagnostics, the business of PathAI that provides anatomic and digital pathology laboratory services.The latest development builds on Quest Diagnostics’ leadership in oncology and subspecialized path ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-12215 Quest Diagnostics Incorporated Delaware 16-1387862 500 Plaza Drive (State of Incorporation) (I.R.S. Employ ...

Quest Diagnostics Incorporated (NYSE:DGX) Q1 2024 Earnings Conference Call April 23, 2024 8:30 AM ET Company Participants Jim Davis - Chairman, Chief Executive Officer, President Sam Samad - Chief Financial Officer Shawn Bevec - Vice President of Investor Relations Conference Call Participants Patrick Donnelly - Citi Ann Hynes - Mizuho Securities Kevin Caliendo - UBS Taji Phillips - Jefferies Erin Wright - Morgan Stanley Michael Cherny - Leerink Partners Jack Meehan - Nephron Research Elizabeth Anderson - ...

Quest Diagnostics Incorporated’s (DGX) first-quarter 2024 adjusted earnings per share (EPS) of $2.04 beat the Zacks Consensus Estimate by 9.7%. However, the metric came in line with the year-ago adjusted figure.Certain one-time expenses, like the ones related to amortization expenses, certain restructuring and integration charges, other expenses and excess tax benefits associated with stock-based compensations, were excluded from the quarter’s adjusted figures.GAAP earnings came in at $1.72 per share, down ...

Quest Diagnostics (DGX) came out with quarterly earnings of $2.04 per share, beating the Zacks Consensus Estimate of $1.86 per share. This compares to earnings of $2.04 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 9.68%. A quarter ago, it was expected that this medical laboratory operator would post earnings of $2.14 per share when it actually produced earnings of $2.15, delivering a surprise of 0.47%.Over the last four qua ...

Quest Diagnostics Reports First Quarter 2024 Financial Results; Raises Guidance for Full Year 2024 Exhibit 99.1 "In addition, our Invigorate initiative, which includes ongoing investments in automation and AI, continued to improve productivity as well as service levels and quality. Given the strength of our business, we are raising our revenue and adjusted earnings guidance for the full year," Mr. Davis said. | | | | | Three Months Ended March 31, | | | --- | --- | --- | --- | --- | --- | | | | 2024 | | 202 ...

First quarter revenues of $2.37 billion, up 1.5% from 2023 First quarter reported diluted earnings per share ("EPS") of $1.72, down 3.4% from 2023; and adjusted diluted EPS of $2.04, flat with 2023 Full year 2024 revenues now expected to be between $9.40 billion and $9.48 billion; reported diluted EPS now expected to be between $7.57 and $7.82; and adjusted diluted EPS expected to be between $8.72 and $8.97 SECAUCUS, N.J., April 23, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leadin ...

Wall Street expects a year-over-year decline in earnings on lower revenues when Quest Diagnostics (DGX) reports results for the quarter ended March 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on April 23. ...

Quest Diagnostics (DGX) is set to release first-quarter 2024 results on Apr 23 before the opening bell.The company posted adjusted earnings per share (EPS) of $2.15 in the last reported quarter, which surpassed the Zacks Consensus Estimate by 0.47%. Quest Diagnostics beat earnings estimates in each of the trailing four quarters, the average surprise being 2.13%.Let’s look at how things have shaped up before this announcement.Factors at PlayBase BusinessIn the first quarter of 2024, the company is likely to ...